“…The aim of the present study was to determine whether the alteration of a C-terminal GAD65Ab epitope, by substituting GAD67-derived amino acids, defines GAD65Ab with increased diagnostic specificity for Type 1 diabetes. [19]; (ii) mouse monoclonal antibody GAD6, which recognises the C terminus of GAD65 [20]; and (iii) human monoclonal islet cell antibodies (MICA: MICA1, MICA2, MICA3, MICA4 and MICA6) [11,17,21]. Group B included standard sera from ten children (aged 11-16 years) newly diagnosed with Type 1 diabetes, which were obtained at the clinical onset of disease [22].…”